iBio advances IBIO-600 into Phase 1 multiple-ascending-dose trial stage after completing single-ascending-dose dosing

PUBT · 1d ago
iBio advances IBIO-600 into Phase 1 multiple-ascending-dose trial stage after completing single-ascending-dose dosing
  • iBio initiated a Phase 1 trial of IBIO-600 in fiscal 2026, moving the company into clinical-stage development.
  • Single-ascending-dose dosing reached 31 of 32 planned participants; no safety issues blocked dose escalation.
  • Multiple-ascending-dose escalation is next, positioning the program for broader evaluation as a muscle-preserving complement to GLP-1 therapies.
  • Preclinical results for IBIO-610 were already presented, supporting potential fat-selective weight loss and reduced weight regain following GLP-1 discontinuation.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. iBio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001420720-26-000019), on August 28, 2026, and is solely responsible for the information contained therein.